Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

Share Price Information for Biome Tech (BIOM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 85.00
Bid: 70.00
Ask: 100.00
Change: 0.00 (0.00%)
Spread: 30.00 (42.857%)
Open: 85.00
High: 85.00
Low: 85.00
Prev. Close: 85.00
BIOM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

24 Jul 2017 07:00

RNS Number : 8093L
Biome Technologies PLC
24 July 2017
 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 ("MAR")

 

24 July 2017

 

Biome Technologies plc

 

("Biome", "the Company" or "the Group")

 

Trading Update

 

Biome Technologies plc, a leading bioplastics and radio frequency technology business, today publishes a trading update for the six months ended 30 June 2017. The unaudited interim results are expected to be announced on 4 September 2017.

 

Total Group revenues for the first half of the year were £3.0m, representing a 38% increase compared to the same period last year (2016: £2.2m).

 

The Directors expect that the Group will report a small profit before interest, tax, depreciation, amortisation, and share option charges for the first half of the year (based on unaudited management accounts).

 

The Group's cash position as at 30 June 2017 was £1.9m (31 December 2016: £1.5m, 31 March 2017 £1.8m), reflecting trading activity and receipt of £0.45m in Q1 under the settlement agreement reported previously.

 

 

Bioplastics Division

Revenues in the Bioplastics division in H1 2017 were £1.2m, 114% ahead of last year (H1 2016: £0.6m). This growth is a result of both good demand for commercialised products from the US single-serve coffee market and growth of revenues from the Company's biodegradable non-woven filter for coffee pods. Lower sales in Q2 versus Q1 are reflective of timings of production runs by customers for outer packaging over the period.

 

The non-woven filter developed over the past three years continues to move towards full commercialisation and pods incorporating this material are now being utilised within a first customer's range. These are being marketed as 100% compostable pods in the consumer market. Further growth from this initial customer is expected as the full product range is converted from oil based to bioplastic materials over the coming months. The Group looks forward to further progress within the Bioplastics division during the second half of the year.

 

 

Stanelco RF Technologies Division

Revenues for H1 2017 in the RF Technologies division were up 10% to £1.7m (H1 2016: £1.6m). Good revenue levels in the period were supported by the build and delivery of several fibre optic furnaces. A solid order book and good enquiry pipeline underpin a very strong outlook for this division for the second half and into 2018.

 

 

Outlook

Biome continues to make progress against the strategy as set out in the Group's full year results announced in March 2017 and against this background the Board remains confident in the Group's outlook for the remainder of the year.

 

- Ends -

 

 

 

For further information please contact: Biome Technologies plc

 

Paul Mines, Chief Executive Officer

Declan Brown, Group Finance Director

www.biometechnologiesplc.com

Tel: +44 (0) 2380 867 100

 

Allenby Capital

David Hart/Richard Short (Nominated Adviser)

Chris Crawford/Kelly Gardiner (Broker)

www.allenbycapital.com

Tel: +44 (0) 20 3328 5656

 

FTI Consulting

Oliver Winters

www.fticonsulting.com

Tel: +44 (0) 20 3727 1535

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTOKDDKABKDPOB
Date   Source Headline
17th Oct 20065:54 pmRNSNotifiable Interest
17th Oct 200610:44 amRNSNotifiable Interest
16th Oct 20063:17 pmRNSNotifiable Interest
12th Oct 200612:35 pmRNSDoc re. Posting of Prospectus
11th Oct 20061:09 pmRNSNotifiable Interest
9th Oct 200611:13 amRNSProposed Placing & Open Offer
5th Oct 200610:25 amRNSFinancing Update
3rd Oct 200612:56 pmRNSStatement re. Press Comment
2nd Oct 20064:41 pmRNSSecond Price Monitoring Extn
2nd Oct 20064:35 pmRNSPrice Monitoring Extension
8th Sep 20067:01 amRNSTrading Statement
17th Aug 20067:44 amRNSTrading Statement
16th Aug 20065:52 pmRNSAdditional Listing - AMEND
14th Aug 200611:55 amRNSAdditional Listing
10th Aug 200612:25 pmRNSRe Contract
14th Jul 20067:56 amRNSInterim Results - Replacement
14th Jul 20067:00 amRNSInterim Results
2nd Jun 200611:26 amRNSNew Ord Share Placing-Amendmt
2nd Jun 20068:45 amRNSNew Ordinary Share Placing
25th May 20067:02 amRNSWrap 100 FDA approval
16th May 200610:43 amRNSAdditional Listing
15th May 20067:01 amRNSAppointment of Adviser
3rd May 20061:05 pmRNSNotifiable Interest
2nd May 20064:58 pmRNSResult of AGM
2nd May 20062:00 pmRNSAGM Statement
10th Apr 20063:12 pmRNSAnnual Report and Accounts
7th Apr 20062:46 pmRNSAdditional Listing
13th Mar 20067:02 amRNSDirectorate Change
28th Feb 20067:02 amRNSPreliminary Results
24th Feb 20067:02 amRNSCooperation with Wal-Mart
14th Feb 20069:07 amRNSAdditional Listing
14th Feb 20067:00 amRNSUS FDA approval for Starpol
9th Feb 200610:42 amRNSIsraCaps new licence terms
9th Feb 20067:02 amRNSRe: BioProgress plc
16th Dec 20057:01 amRNSFunding for R&D facility
16th Dec 20057:01 amRNSPre Close Update
14th Dec 20057:01 amRNSLandmark deal with Perseco
8th Dec 200510:25 amRNSShare Listing Application
30th Nov 20055:40 pmRNSDirectorate Change
28th Nov 20059:24 amRNSBoard Changes
8th Nov 20057:01 amRNSPatent sale process update
3rd Nov 20054:47 pmRNSExercise of Options
1st Nov 20057:02 amRNSChange of Adviser
12th Oct 20057:00 amRNSApproval of Starpol
3rd Oct 20057:00 amRNSPatent Disposal & Update
22nd Sep 20057:02 amRNSRe Agreement
12th Sep 20057:03 amRNSDevelopment of capsule
5th Sep 20057:03 amRNSRe: Completion
30th Aug 20053:30 pmRNSDoc re. Result of EGM
30th Aug 200511:08 amRNSEGM Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.